ESMO 2022: Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy
“Even with notable progress in the treatment of metastatic renal cell carcinoma (RCC), there are…
Browsing: ESMO
ESMO 2022: Sotorasib demonstrates superior PFS versus docetaxel for previously treated NSCLC with KRAS G12C mutation
“In the first Phase 3 randomised clinical trial for a KRASG12C inhibitor, oral sotorasib demonstrated…
ESMO 2022: Cell therapy improves PFS in advanced melanoma, first phase 3 study shows
A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard…
ESMO 2022: ADAURA trial results – early-stage non-small cell lung cancer
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year…
ESMO 2022: A new era of early cancer detection with blood test may change cancer screening paradigms
Cancer doctors, care providers and payers need to get ready for a major shift in…
ESMO 2022: Scientists discover how air pollution may trigger lung cancer in never-smokers
A new mechanism has been identified through which very small pollutant particles in the air…
ESMO 2022: Impressive results for the patients with rare cancers in the DeFi Trial
Significant improvement in progression free survival and response rate combined with reduced symptoms and better…
ESMO 2022: The frontline oncology workforce unites to reduce the burden of cancer before it hits
ESMO, the leading professional organisation for medical oncology, together with EONS, a pan-European membership organisation…
ESMO: Recommendations on the use of circulating tumour DNA assays for cancer patients
ESMO has released a report from the ESMO Precision Medicine Working Group on recommendations on…
ESMO: New phase III data show tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced oesophageal cancer in combination with chemotherapy
New results from the phase III RATIONALE 306 trial show that tislelizumab plus chemotherapy significantly improved…